Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-Plorer trial of rivaroxaban versus heparin during elective PCI
NL-OMON35762Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rivaroxaban in coronary arteriosclerosis (4 arms), sponsored by Bayer. Primary endpoint: Composite anticoagulant effect during index PCI. Started Oct 2011; status: active, not recruiting.
02
Drugs
rivaroxaban
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON35762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35762.